Reading ANVS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANVS free→Reading ANVS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANVS free→QuarterlyIQ Insights · ANVS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On May 20, 2026, Annovis Bio, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”), dated as of May 20, 2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”) (i) an aggregate of 7,895,000 shares of common stock (the “Shares”), $0.0001 par value per share (the “Common Stock”), of the Company and (ii) acco…
Results of Operations and Financial Condition. On May 15, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.
Entry into a Material Definitive Agreement. Underwritten Registered Direct Offering On April 9, 2026, Annovis Bio, Inc. (the “Company”) entered into (i) an Underwriting Agreement (the “Underwriting Agreement”), dated as of April 9, 2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in an underwritten registered direct offering (the “Offering”) (i) an aggregate of 5,263,156 shares of common stock (the “Shares”), $0.0001…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements Effective March 23, 2026, Mark Guerin is no longer employed as as Chief Financial Officer of Annovis Bio, Inc. (the “Company”) . Mr. Guerin ’s departure did not arise from any disagreement with the Company or any matter relating to the Company’s operations, policies or practices. The Company anticipates that the board of directors of the Company will appoint Maria Macc…
Results of Operations and Financial Condition. On March 16, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.
Results of Operations and Financial Condition. On November 12, 2025, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the quarter and nine months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.
Other Events. In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Loeb & Loeb LLP, regarding the validity of the Shares, the Placement Agent Warrant, and the shares underlying the Placement Agent Warrants being registered, which opinion is attached hereto as Exhibit 5.1 and is incorporated herein by reference.
Entry into a Material Definitive Agreement. Registered Direct Offering On October 26, 2025 (the “Agreement Date”), Annovis Bio, Inc. (the “Company”) entered into (i) a Securities Purchase Agreement (the “Purchase Agreement”), with the purchasers signatory thereto (the “Purchasers”) pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”) an aggregate of 597,561 shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”…
Other Events. In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Loeb & Loeb LLP, regarding the validity of the Shares, the Pre-Funded Warrants, the Placement Agent Warrant, and the shares underlying the Pre-Funded Warrants and the Placement Agent Warrants being registered, which opinion is attached hereto as Exhibit 5.1 and is incorporated herein by reference.
Entry into a Material Definitive Agreement. Registered Direct Offering On October 10, 2025 (the “Agreement Date”), Annovis Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”), with the purchasers signatory thereto (the “Purchasers”) pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”) an aggregate of 3,150,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements Effective September 25, 2025, Annovis Bio, Inc. (the “Company”) appointed Mark Guerin, age 57, as Chief Financial Officer of the Company. Prior to joining the Company, Mr. Guerin served as Chief Financial Officer of Onconova Therapeutics, now known as Traws Pharma, Inc. (Nasdaq: TRAW) from 2016 through February, 2025. Mr. Guerin has a bachelor’s degree in accounting fr…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements On August 11, 2025, Annovis Bio, Inc. (the “Company”) received the resignation of Andrew Walsh as Vice President of Finance, the Company’s Principal Financial Officer, effective August 22, 2025. Mr. Walsh’s resignation did not arise from any disagreement with the Company or any matter relating to the Company’s operations, policies or practices. On August 15, 2025, the…
Results of Operations and Financial Condition. On August 12, 2025, Annovis Bio, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Principal Financial Officer On May 9, 2025, the Board of Directors appointed Andrew Walsh, the Company’s current Vice President of Finance, as the Company’s Principal Financial Officer. Mr. Walsh, age 36, has served as the Company's Vice President of Finance since December 2023. He holds a Bachelor's degree in Accounting from Drexel…
Results of Operations and Financial Condition. On May 13, 2025, Annovis Bio, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2025 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.
Departure of Certain Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers As previously disclosed, on December 4, 2024, the Company appointed William Fricker to serve as Interim Chief Financial Officer. On March 27, 2025, by mutual agreement, Mr. Fricker will no longer serve as interim Chief Financial Officer. Mr. Fricker’s departure was not due to any disagreement or dispute with the Company or its Board of Direct…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 26, 2025, Annovis Bio, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average market capitalization over a consecutive 30 trading-day period was less than $50…
Results of Operations and Financial Condition. On March 21, 2025, Annovis Bio, Inc. issued a press release announcing its financial results for the fourth quarter and the fiscal year ended December 31, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.
Entry into a Material Definitive Agreement. On February 3, 2025, Annovis Bio, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with ThinkEquity LLC, acting as representative of the underwriters (“ ThinkEquity ”) with respect to an underwritten public offering of 5,250,000 units of the Company, each unit consisting of one share of its common stock, par value $0.0001 per share (the “ Common Stock ”) and one warrant to purchase one share of the Compa…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.